The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
The FTC can challenge deals to keep generic drugs off the market, reports CNBC's Hampton Pearson.
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
Pfizer announced a $2.15 billion settlement from Teva Pharmaceuticals and and Sun Pharmaceutical for patent infringement on its drug Protonix.
Matthew Foy, partner, SR One and Peter Silvester, president of Life Technologies, discuss whether personalised medicine is a true disruptor or just for the rich.
GlaxoSmithKline fired the head of its R&D operations in China after a tipster spurred an inquiry that found "misrepresented" data were used in a multiple sclerosis study.
Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.
Can someone else patent your genes? The Supreme Court is scheduled to rule some time this month on that question. NBCNews.com reports.
AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
Forest Laboratories is trying to avert yet another bitter proxy battle with billionaire investor Carl Icahn ahead of its annual investor meeting this summer, sources said.
Joseph Jimenez, CEO of Novartis, says the pharmaceutical company is investing heavily to introduce new drugs in China as the spotlight shifts from infectious to chronic disease.
CNBC's Jackie DeAngelis reports which big pharma companies are leading in the fight against cancer.
Dr. Anthony Coles, Onyx Pharmaceuticals CEO & president, discusses promising results shown with liver cancer drug Nexavar, and reveals other new drugs coming to the market.
Hal Barron, Roche/Genentech chief medical officer, shares several new developments in treating cancer, including some promising results with Roche/Genentech 's Avastin.
“I want to tell you about a new cancer fighting biotech name that’s probably not on your radar screen,” said Cramer.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
In two big M&A deals, Valeant Pharmaceuticals agreed to buy Bausch & Lomb for $8.7 billion, and AstraZeneca agreed to acquire Omthera Pharmaceuticals for as much as $443 million.
Merck inked a $5 billion share repurchase agreement with Goldman Sachs, as the drug giant looks to prop up shareholder value in face of competition from generics makers.
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
Cramer has been looking at long-term losers to see if any show potential. He’s found something.